Cogent Biosciences to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
Cogent Biosciences (Nasdaq: COGT) announced that CEO Andrew Robbins will participate in a fireside chat and one-on-one investor meetings at the Piper Sandler 33rd Annual Healthcare Conference from November 29 to December 2, 2021. The pre-recorded chat will be available starting at 10:00 a.m. ET and accessible until the conference concludes. Cogent focuses on precision therapies for genetically defined diseases, with its lead program, bezuclastinib, targeting the KIT D816V mutation linked to systemic mastocytosis and advanced gastrointestinal stromal tumors.
- None.
- None.
CAMBRIDGE, Mass. and BOULDER, Colo., Nov. 22, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President will participate in a fireside chat and one-on-one investor meetings during the Piper Sandler 33rd Annual Healthcare Conference, taking place virtually November 29 – December 2, 2021.
The pre-recorded fireside chat will be available to conference attendees starting at 10:00 a.m. ET today and will remain available through the end of the conference on Thursday, December 2. Access to the recording will be available under the "Events" tab on the investor relations section of the Cogent Biosciences website at: https://investors.cogentbio.com/events.
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the newly formed Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. Cogent Biosciences is based in Cambridge, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn. Information that may be important to investors will be routinely posted on our website and Twitter.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cogent-biosciences-to-present-at-piper-sandler-33rd-annual-virtual-healthcare-conference-301429300.html
SOURCE Cogent Biosciences, Inc.
FAQ
When will Cogent Biosciences present at the Piper Sandler 33rd Annual Healthcare Conference?
Who is representing Cogent Biosciences at the conference?
How can I access the pre-recorded fireside chat by Cogent Biosciences?
What is the focus of Cogent Biosciences?
What is the lead clinical program of Cogent Biosciences?
